Pharmaceutical Analysis & Statistics in Europe Countries, August 2014

Talk to Louis

+1 718 618 4302

Publishers

You might be interested in: therapeutics, drug, cancer, more »

1-50 of about 13 000 reports

Purchase Reports From Reputable Market Research Publishers

PharmaPoint: Major Depressive Disorder - 5EU Drug Forecast and Market Analysis to 2023

PharmaPoint: Major Depressive Disorder - 5EU Drug Forecast and Market Analysis to 2023

  • $ 6 995
  • Industry report
  • May 2014
  • by Global Data

PharmaPoint: Major Depressive Disorder - 5EU Drug Forecast and Market Analysis to 2023 Summary Major depressive disorder (MDD) is one of the most common psychiatric diseases worldwide. The MDD market is ...

  • Industries : Pathology
  • Countries : Spain, Italy, France, Germany, United Kingdom, Europe, World
MarketVIEW: allergic immunotherapies

MarketVIEW: allergic immunotherapies

  • $ 4 495
  • Industry report
  • July 2014
  • by VacZine Analytics Group Of Assay Advantage Ltd

Allergy or Allergic rhinitis is caused by sensitivity to a number of environmental factors including grass, tree and weed pollens, house dust mite and cat dander. Prevalence in adults can range from 17 ...

  • Industries : Therapy
  • Countries : Japan, World, Europe, France, Netherlands, United States, Spain, Italy, Germany, United Kingdom, Denmark
MarketVIEW - Meningitis ACWY vaccines

MarketVIEW - Meningitis ACWY vaccines

  • $ 4 495
  • Industry report
  • July 2014
  • by VacZine Analytics Group Of Assay Advantage Ltd

Gram-negative Neisseria meningitidis (N.men) is an important contributor to bacterial meningitis. Of the estimated 1.2 million cases which occur each year (WHO Figures), N.men is thought to be responsible ...

  • Industries : Drug and Medication
  • Countries : World, United States, Europe, Chile, South America, Saudi Arabia, Africa, United Kingdom, South Korea, Brazil, France, Asia, Argentina, Indonesia, Colombia, Mexico, Spain, Italy, Greece, Germany, Austria, Pakistan, Malaysia, North America
EpiCast Report: Acute Coronary Syndrome (ACS) - Epidemiology Forecast to 2023

EpiCast Report: Acute Coronary Syndrome (ACS) - Epidemiology Forecast to 2023

  • $ 3 995
  • Industry report
  • July 2014
  • by Global Data

EpiCast Report: Acute Coronary Syndrome (ACS) - Epidemiology Forecast to 2023 Summary Acute coronary syndrome (ACS) is a serious cardiovascular disease associated with high healthcare costs, frequent recurrences ...

  • Industries : Pathology
  • Countries : Germany, World, United States, Spain, United Kingdom, Italy, France, Japan
Critical Care Therapeutics in Major Developed Markets to 2020 - New and Late-Stage Four-Factor PCCs and Recombinant Products to Drive Market

Critical Care Therapeutics in Major Developed Markets to 2020 - New and Late-Stage Four-Factor PCCs and Recombinant Products to Drive Market

  • $ 3 500
  • Industry report
  • July 2014
  • by GBI Research

Critical Care Therapeutics in Major Developed Markets to 2020 - New and Late-Stage Four-Factor PCCs and Recombinant Products to Drive Market Summary GBI Research, the leading business intelligence provider, ...

  • Industries : Therapy
  • Countries : France, Canada, Japan, Spain, Italy, Germany, United States, Europe, United Kingdom, World
Glioblastoma Multiforme Therapeutics in Major Developed Markets to 2019 - Growth to Hinge on the Success of Personalized Vaccine Following Early Approval in Germany

Glioblastoma Multiforme Therapeutics in Major Developed Markets to 2019 - Growth to Hinge on the Success of Personalized Vaccine Following Early Approval in Germany

  • $ 3 500
  • Industry report
  • June 2014
  • by GBI Research

Glioblastoma Multiforme Therapeutics in Major Developed Markets to 2019 - Growth to Hinge on the Success of Personalized Vaccine Following Early Approval in Germany Summary GBI Research, a leading business ...

  • Industries : Therapy
  • Countries : World, Germany, Japan, United States, Europe, North America, Canada, Spain, Italy, France, United Kingdom
Brexpiprazole (Major Depressive Disorder) - Forecast and Market Analysis to 2023

Brexpiprazole (Major Depressive Disorder) - Forecast and Market Analysis to 2023

  • $ 3 495
  • Industry report
  • May 2014
  • by Global Data

Brexpiprazole (Major Depressive Disorder) - Forecast and Market Analysis to 2023 Summary Major depressive disorder (MDD) is one of the most common psychiatric diseases worldwide. The MDD market is a crowded ...

  • Industries : Pathology
  • Countries : Australia, World, Spain, Italy, France, Germany, Japan, Europe, United States, United Kingdom, Oceania
Cariprazine (Major Depressive Disorder) - Forecast and Market Analysis to 2023

Cariprazine (Major Depressive Disorder) - Forecast and Market Analysis to 2023

  • $ 3 495
  • Industry report
  • May 2014
  • by Global Data

Cariprazine (Major Depressive Disorder) - Forecast and Market Analysis to 2023 Summary Major depressive disorder (MDD) is one of the most common psychiatric diseases worldwide. The MDD market is a crowded ...

  • Industries : Pathology
  • Countries : Australia, World, Spain, Italy, France, Germany, Japan, United States, United Kingdom, Europe, Oceania
ALKS-5461 (Major Depressive Disorder) - Forecast and Market Analysis to 2023

ALKS-5461 (Major Depressive Disorder) - Forecast and Market Analysis to 2023

  • $ 3 495
  • Industry report
  • May 2014
  • by Global Data

ALKS-5461 (Major Depressive Disorder) - Forecast and Market Analysis to 2023 Summary Major depressive disorder (MDD) is one of the most common psychiatric diseases worldwide. The MDD market is a crowded ...

  • Industries : Pathology
  • Countries : Australia, World, Spain, Italy, France, Germany, Japan, United States, United Kingdom, Europe, Oceania
Amitifadine (Major Depressive Disorder) - Forecast and Market Analysis to 2023

Amitifadine (Major Depressive Disorder) - Forecast and Market Analysis to 2023

  • $ 3 495
  • Industry report
  • May 2014
  • by Global Data

Amitifadine (Major Depressive Disorder) - Forecast and Market Analysis to 2023 Summary Major depressive disorder (MDD) is one of the most common psychiatric diseases worldwide. The MDD market is a crowded ...

  • Industries : Pathology
  • Countries : Australia, World, Spain, Italy, France, Germany, Japan, United States, United Kingdom, Europe, Oceania
GLYX-13 (Major Depressive Disorder) - Forecast and Market Analysis to 2023

GLYX-13 (Major Depressive Disorder) - Forecast and Market Analysis to 2023

  • $ 3 495
  • Industry report
  • May 2014
  • by Global Data

GLYX-13 (Major Depressive Disorder) - Forecast and Market Analysis to 2023 Summary Major depressive disorder (MDD) is one of the most common psychiatric diseases worldwide. The MDD market is a crowded ...

  • Industries : Pathology
  • Countries : Australia, World, Spain, Italy, France, Germany, Japan, United States, United Kingdom, Europe, Oceania
Tedatioxetine (Major Depressive Disorder) - Forecast and Market Analysis to 2023

Tedatioxetine (Major Depressive Disorder) - Forecast and Market Analysis to 2023

  • $ 3 495
  • Industry report
  • May 2014
  • by Global Data

Tedatioxetine (Major Depressive Disorder) - Forecast and Market Analysis to 2023 Summary Major depressive disorder (MDD) is one of the most common psychiatric diseases worldwide. The MDD market is a crowded ...

  • Industries : Pathology
  • Countries : Australia, World, Spain, Italy, France, Germany, Japan
Lexapro (Major Depressive Disorder) - Forecast and Market Analysis to 2023

Lexapro (Major Depressive Disorder) - Forecast and Market Analysis to 2023

  • $ 3 495
  • Industry report
  • May 2014
  • by Global Data

Lexapro (Major Depressive Disorder) - Forecast and Market Analysis to 2023 Summary Major depressive disorder (MDD) is one of the most common psychiatric diseases worldwide. The MDD market is a crowded ...

  • Industries : Pathology
  • Countries : Australia, World, Spain, Italy, France, Germany, Japan, United States, United Kingdom, Europe, Oceania
ETS6103 (Major Depressive Disorder) - Forecast and Market Analysis to 2023

ETS6103 (Major Depressive Disorder) - Forecast and Market Analysis to 2023

  • $ 3 495
  • Industry report
  • May 2014
  • by Global Data

ETS6103 (Major Depressive Disorder) - Forecast and Market Analysis to 2023 Summary Major depressive disorder (MDD) is one of the most common psychiatric diseases worldwide. The MDD market is a crowded ...

  • Industries : Pathology
  • Countries : Australia, World, Spain, Italy, France, Germany, Japan, United States, United Kingdom, Europe, Oceania
Effexor (Major Depressive Disorder) - Forecast and Market Analysis to 2023

Effexor (Major Depressive Disorder) - Forecast and Market Analysis to 2023

  • $ 3 495
  • Industry report
  • May 2014
  • by Global Data

Effexor (Major Depressive Disorder) - Forecast and Market Analysis to 2023 Summary Major depressive disorder (MDD) is one of the most common psychiatric diseases worldwide. The MDD market is a crowded ...

  • Industries : Pathology
  • Countries : Australia, World, United States, Spain, Italy, France, Germany, United Kingdom, Europe, Oceania
Cymbalta (Major Depressive Disorder) - Forecast and Market Analysis to 2023

Cymbalta (Major Depressive Disorder) - Forecast and Market Analysis to 2023

  • $ 3 495
  • Industry report
  • May 2014
  • by Global Data

Cymbalta (Major Depressive Disorder) - Forecast and Market Analysis to 2023 Summary Major depressive disorder (MDD) is one of the most common psychiatric diseases worldwide. The MDD market is a crowded ...

  • Industries : Pathology
  • Countries : Australia, Japan, World, Spain, Italy, France, Germany, United States, United Kingdom, Europe, Oceania
Brintellix (Major Depressive Disorder) - Forecast and Market Analysis to 2023

Brintellix (Major Depressive Disorder) - Forecast and Market Analysis to 2023

  • $ 3 495
  • Industry report
  • May 2014
  • by Global Data

Brintellix (Major Depressive Disorder) - Forecast and Market Analysis to 2023 Summary Major depressive disorder (MDD) is one of the most common psychiatric diseases worldwide. The MDD market is a crowded ...

  • Industries : Pathology
  • Countries : Australia, World, Spain, Italy, France, Germany, Japan, Europe, United States, United Kingdom, Oceania
Abilify (Major Depressive Disorder) - Forecast and Market Analysis to 2023

Abilify (Major Depressive Disorder) - Forecast and Market Analysis to 2023

  • $ 3 495
  • Industry report
  • May 2014
  • by Global Data

Abilify (Major Depressive Disorder) - Forecast and Market Analysis to 2023 Summary Major depressive disorder (MDD) is one of the most common psychiatric diseases worldwide. The MDD market is a crowded ...

  • Industries : Pathology
  • Countries : Australia, Japan, World, Spain, Italy, France, Germany, United States, United Kingdom, Europe, Oceania
Global Vitamin and Provitamin Market to 2018 - Market Size, Growth, and Forecasts in Nearly 70 Countries

Global Vitamin and Provitamin Market to 2018 - Market Size, Growth, and Forecasts in Nearly 70 Countries

  • $ 2 488
  • Industry report
  • July 2014
  • by MarketSizeInfo

This is a comprehensive publication that enables readers the critical perspectives to be able to evaluate the world market for vitamins and provitamins. The publication provides the market size, growth ...

  • Industries : Vitamin and Supplement
  • Countries : World, Europe, Asia, South America, Czech Republic, South Korea, Philippines, Australia, Argentina, United States, United Kingdom, Netherlands, Macedonia, Lithuania, Sri Lanka, Singapore, Kazakhstan, Indonesia, Azerbaijan, South Africa, Africa, Uruguay, Ecuador, Chile, Colombia, Bolivia, Panama, Mexico, Canada, Ukraine, Sweden, Spain, Slovenia, Slovakia (slovak Republic), Russian Federation, Romania, Portugal, Poland, Norway, Moldova, Republic Of, Latvia, Italy, Ireland, Hungary, Greece, France, Germany, Finland, Estonia, Denmark, Bulgaria, Belgium, Austria, Vietnam, Thailand, Pakistan, Malaysia, Lebanon, Jordan, Japan, India, China, Georgia, Armenia, Senegal, Nigeria, Morocco, Ghana, Ethiopia, Egypt, North America, Peru, Oman
Vaginal Atrophy (Atrophic Vaginitis) - Pipeline Review, H2 2014

Vaginal Atrophy (Atrophic Vaginitis) - Pipeline Review, H2 2014

  • $ 2 000
  • Company report
  • August 2014
  • by Global Markets Direct

Vaginal Atrophy (Atrophic Vaginitis) - Pipeline Review, H2 2014 Summary Global Markets Direct's, ‘Vaginal Atrophy (Atrophic Vaginitis) - Pipeline Review, H2 2014', provides an overview of the Vaginal ...

  • Industries : Pathology
  • Countries : World, Sweden
Liver Failure - Pipeline Review, H2 2014

Liver Failure - Pipeline Review, H2 2014

  • $ 2 000
  • Company report
  • July 2014
  • by Global Markets Direct

Liver Failure - Pipeline Review, H2 2014 Summary Global Markets Direct's, ‘Liver Failure - Pipeline Review, H2 2014', provides an overview of the Liver Failure's therapeutic pipeline. This report provides ...

  • Industries : Drug Discovery and Development
  • Countries : World, Spain
Women Infertility - Pipeline Review, H2 2014

Women Infertility - Pipeline Review, H2 2014

  • $ 2 000
  • Company report
  • July 2014
  • by Global Markets Direct

Women Infertility - Pipeline Review, H2 2014 Summary Global Markets Direct's, ‘Women Infertility - Pipeline Review, H2 2014', provides an overview of the Women Infertility's therapeutic pipeline. This ...

  • Industries : Drug and Medication
  • Countries : World, Switzerland
Recurrent Glioblastoma Multiforme (GBM) - Pipeline Review, H1 2014

Recurrent Glioblastoma Multiforme (GBM) - Pipeline Review, H1 2014

  • $ 2 000
  • Company report
  • June 2014
  • by Global Markets Direct

Recurrent Glioblastoma Multiforme (GBM) - Pipeline Review, H1 2014 Summary Global Markets Direct's, ‘Recurrent Glioblastoma Multiforme (GBM) - Pipeline Review, H1 2014', provides an overview of the ...

  • Industries : Pathology
  • Countries : Belgium
Genital Warts (Condylomata Acuminata) - Pipeline Review, H1 2014

Genital Warts (Condylomata Acuminata) - Pipeline Review, H1 2014

  • $ 2 000
  • Company report
  • June 2014
  • by Global Markets Direct

Genital Warts (Condylomata Acuminata) - Pipeline Review, H1 2014 Summary Global Markets Direct's, ‘Genital Warts (Condylomata Acuminata) - Pipeline Review, H1 2014', provides an overview of the Genital ...

  • Industries : Pathology
  • Countries : World, Czech Republic, Taiwan
Intermittent Claudication - Pipeline Review, H1 2014

Intermittent Claudication - Pipeline Review, H1 2014

  • $ 2 000
  • Company report
  • June 2014
  • by Global Markets Direct

Intermittent Claudication - Pipeline Review, H1 2014 Summary Global Markets Direct's, ‘Intermittent Claudication - Pipeline Review, H1 2014', provides an overview of the Intermittent Claudication's therapeutic ...

  • Industries : Drug Discovery and Development
  • Countries : South Korea, World, Germany, Israel
Pompe Disease - Pipeline Review, H1 2014

Pompe Disease - Pipeline Review, H1 2014

  • $ 2 000
  • Company report
  • June 2014
  • by Global Markets Direct

Pompe Disease - Pipeline Review, H1 2014 Summary Global Markets Direct's, ‘Pompe Disease - Pipeline Review, H1 2014', provides an overview of the Pompe Disease's therapeutic pipeline. This report provides ...

  • Industries : Pathology
  • Countries : Belgium, World
Global Proton Therapy Outlook 2018

Global Proton Therapy Outlook 2018

  • $ 2 000
  • Industry report
  • June 2014
  • by RNCOS

Proton Therapy, the new kid on the block for cancer treatment, has garnered worldwide attention in the past few years. Due to its ability to deliver higher doses of radiation to the targeted areas without ...

  • Industries : Therapy
  • Countries : Germany, China, Japan, World
Latvia Pharmaceuticals and Healthcare Industry Update Quarter 4 2011

Latvia Pharmaceuticals and Healthcare Industry Update Quarter 4 2011

  • $ 1 300
  • Industry report
  • August 2014
  • by Business Monitor International

BMI View: Latvia's disease profile and relatively low per-capita consumption of pharmaceuticals (compared with the rest of developed Europe) is a clear illustration of the need for innovative medicines. ...

  • Industries : Drug and Medication
  • Countries : Latvia
Croatia Pharmaceuticals and Healthcare Industry Update Quarter 4 2011

Croatia Pharmaceuticals and Healthcare Industry Update Quarter 4 2011

  • $ 1 300
  • Industry report
  • August 2014
  • by Business Monitor International

BMI View: Croatia’s pharmaceutical industry appears relatively stable, recording 0.1% growth in 2010 – a year in which economic challenges were sizeable. Compared with its south eastern European neighbours, ...

  • Industries : Pharmaceutical
  • Countries : Croatia
Portugal Pharmaceuticals and Healthcare Industry Update Quarter 3 2012

Portugal Pharmaceuticals and Healthcare Industry Update Quarter 3 2012

  • $ 1 300
  • Industry report
  • July 2014
  • by Business Monitor International

Includes 3 FREE quarterly updates BMI View: A year has passed since the EU/IMF/ECB’s rescue package was approved, and the obligations that form part of the economic adjustment programme have had, and ...

  • Industries : Generic Drug
  • Countries : Portugal
About 8 900 reports

Download Unlimited Documents from Trusted Public Sources

Pathology Description in the UK

  • Infection Reports
  • August 2014
    4 pages
  • Hepatitis A  

    Infectious Dise...  

    Hepatitis C  

  • United Kingdom  

    Europe  

View report >

47 Companies

Read our Company Profiles

GlaxoSmithKline P.L.C.

United States

GlaxoSmithKline PLC

United Kingdom

AstraZeneca PLC

United Kingdom

Novartis Inc.

Switzerland

ReportLinker is an award-winning market research solution that finds, filters and organizes the latest industry data so you get all the market research you need - quickly, in one place.